Cargando…

Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients

INTRODUCTION: Breakthrough COVID-19 may occur in vaccinated people, and may result from declining vaccine effectiveness or highly transmittable SARS-CoV-2 variants, such as the B.167.2 (delta) variant. We investigated risk factors and outcomes for infection with the delta variant among vaccinated he...

Descripción completa

Detalles Bibliográficos
Autores principales: Wand, Ori, Nacasch, Naomi, Fadeela, Ayman, Shashar, Moshe, Grupper, Ayelet, Benchetrit, Sydney, Erez, Daniel, Shitrit, Pnina, Cohen-Hagai, Keren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852959/
https://www.ncbi.nlm.nih.gov/pubmed/35175577
http://dx.doi.org/10.1007/s40620-022-01245-9
_version_ 1784653138507071488
author Wand, Ori
Nacasch, Naomi
Fadeela, Ayman
Shashar, Moshe
Grupper, Ayelet
Benchetrit, Sydney
Erez, Daniel
Shitrit, Pnina
Cohen-Hagai, Keren
author_facet Wand, Ori
Nacasch, Naomi
Fadeela, Ayman
Shashar, Moshe
Grupper, Ayelet
Benchetrit, Sydney
Erez, Daniel
Shitrit, Pnina
Cohen-Hagai, Keren
author_sort Wand, Ori
collection PubMed
description INTRODUCTION: Breakthrough COVID-19 may occur in vaccinated people, and may result from declining vaccine effectiveness or highly transmittable SARS-CoV-2 variants, such as the B.167.2 (delta) variant. We investigated risk factors and outcomes for infection with the delta variant among vaccinated hemodialysis patients. METHODS: Patients on maintenance hemodialysis who received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine were analysed according to having developed COVID-19 (study group) or not (control group), in a retrospective, observational, comparative study. We compared risk-factors for developing breakthrough COVID-19 and assessed clinical outcomes, including 30-day mortality rates. RESULTS: Twenty-four cases of breakthrough SARS-CoV-2 infection were compared to 91 controls without infection. Breakthrough infection was associated with chronic immunosuppressive treatment, hematological malignancies, and low antibody levels against SARS-CoV-2 spike protein. All COVID-19 cases occurred at least 5 months after vaccination, and most were caused by the B.1.617.2 variant (at least 23/24 cases). COVID-19 was categorized as severe or critical disease in 11/24 patients (46%), and 54% required hospitalization and COVID-19-directed treatment. The source of infection was nosocomial in 6/24 cases (25%), and healthcare-related in 3/24 (12.5%). Mortality rate was 21%. Overall mortality was significantly higher in patients who developed COVID-19 than in controls (odds ratio for all-cause mortality 7.6, 95% CI 1.4–41, p = 0.002). CONCLUSIONS: Breakthrough COVID-19 with the B.1.617.2 variant can occur in vaccinated hemodialysis patients and is associated with immunosuppression and weaker humoral response to vaccination. Infections may be nosocomial and result in significant morbidity and mortality. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-022-01245-9.
format Online
Article
Text
id pubmed-8852959
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88529592022-02-18 Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients Wand, Ori Nacasch, Naomi Fadeela, Ayman Shashar, Moshe Grupper, Ayelet Benchetrit, Sydney Erez, Daniel Shitrit, Pnina Cohen-Hagai, Keren J Nephrol original Article INTRODUCTION: Breakthrough COVID-19 may occur in vaccinated people, and may result from declining vaccine effectiveness or highly transmittable SARS-CoV-2 variants, such as the B.167.2 (delta) variant. We investigated risk factors and outcomes for infection with the delta variant among vaccinated hemodialysis patients. METHODS: Patients on maintenance hemodialysis who received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine were analysed according to having developed COVID-19 (study group) or not (control group), in a retrospective, observational, comparative study. We compared risk-factors for developing breakthrough COVID-19 and assessed clinical outcomes, including 30-day mortality rates. RESULTS: Twenty-four cases of breakthrough SARS-CoV-2 infection were compared to 91 controls without infection. Breakthrough infection was associated with chronic immunosuppressive treatment, hematological malignancies, and low antibody levels against SARS-CoV-2 spike protein. All COVID-19 cases occurred at least 5 months after vaccination, and most were caused by the B.1.617.2 variant (at least 23/24 cases). COVID-19 was categorized as severe or critical disease in 11/24 patients (46%), and 54% required hospitalization and COVID-19-directed treatment. The source of infection was nosocomial in 6/24 cases (25%), and healthcare-related in 3/24 (12.5%). Mortality rate was 21%. Overall mortality was significantly higher in patients who developed COVID-19 than in controls (odds ratio for all-cause mortality 7.6, 95% CI 1.4–41, p = 0.002). CONCLUSIONS: Breakthrough COVID-19 with the B.1.617.2 variant can occur in vaccinated hemodialysis patients and is associated with immunosuppression and weaker humoral response to vaccination. Infections may be nosocomial and result in significant morbidity and mortality. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40620-022-01245-9. Springer International Publishing 2022-02-17 2022 /pmc/articles/PMC8852959/ /pubmed/35175577 http://dx.doi.org/10.1007/s40620-022-01245-9 Text en © The Author(s) under exclusive licence to Italian Society of Nephrology 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle original Article
Wand, Ori
Nacasch, Naomi
Fadeela, Ayman
Shashar, Moshe
Grupper, Ayelet
Benchetrit, Sydney
Erez, Daniel
Shitrit, Pnina
Cohen-Hagai, Keren
Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients
title Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients
title_full Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients
title_fullStr Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients
title_full_unstemmed Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients
title_short Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients
title_sort humoral response and breakthrough infections with sars-cov-2 b.1.617.2 variant in vaccinated maintenance hemodialysis patients
topic original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852959/
https://www.ncbi.nlm.nih.gov/pubmed/35175577
http://dx.doi.org/10.1007/s40620-022-01245-9
work_keys_str_mv AT wandori humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients
AT nacaschnaomi humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients
AT fadeelaayman humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients
AT shasharmoshe humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients
AT grupperayelet humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients
AT benchetritsydney humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients
AT erezdaniel humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients
AT shitritpnina humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients
AT cohenhagaikeren humoralresponseandbreakthroughinfectionswithsarscov2b16172variantinvaccinatedmaintenancehemodialysispatients